Management agrees and is on record to that effect.
It’s a pretty long longshot, but ENTA could conceivably reduce its tax rate by buying a foreign company and doing a tax inversion. (The new US Treasury rules on tax inversions rules wouldn’t be much of an impediment for a company like ENTA.)
If ENTA in-licenses compounds, the most likely areas are virology and liver diseases (but not HCV, as noted above). Buying a whole company working in these areas is also a possibility.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.